- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04634877
자궁내막암으로 새로 진단된 참가자를 대상으로 치료 목적으로 수술 후 방사선 요법을 포함하거나 포함하지 않는 보조 화학 요법과 병용한 Pembrolizumab(MK-3475) 연구(MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
새로 진단된 고위험 자궁내막암의 치료 의도를 가진 수술 후 치료를 위해 방사선 요법을 포함하거나 포함하지 않는 보조 화학요법과 위약을 병용한 Pembrolizumab 대 위약의 3상, 무작위, 이중 맹검 연구(KEYNOTE-B21 / ENGOT-en11 / GOG- 3053)
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Thessaloniki, 그리스, 546 45
- Euromedica General Clinic of Thessaloniki ( Site 2422)
-
-
Achaia
-
Pátrai, Achaia, 그리스, 263 35
- General Hospital of Patras. St Andrews ( Site 2421)
-
-
Attica
-
Athens, Attica, 그리스, 115 28
- Geniko Panepistimako Nosokomeio ARETEIO ( Site 2423)
-
Athens, Attica, 그리스, 115 28
- Perifereiako Geniko Nosokomeio ALEXANDRA ( Site 2425)
-
Chaïdári, Attica, 그리스, 124 62
- Athens University Hospital ATTIKON ( Site 2424)
-
Marousi, Attica, 그리스, 151 23
- Hospital Hygeia ( Site 2426)
-
-
-
-
-
Oslo, 노르웨이, 0310
- Oslo Universitetssykehus Radiumhospitalet ( Site 2151)
-
-
Troms
-
Tromsø, Troms, 노르웨이, 9019
- University Hospital of North Norway ( Site 2153)
-
-
Vest-Agder
-
Kristiansand, Vest-Agder, 노르웨이, 4615
- Soerlandet sykehus HF Kristiansand ( Site 2152)
-
-
-
-
-
Changhua, 대만, 50006
- Changhua Christian Hospital ( Site 4095)
-
Taichung, 대만, 407
- Taichung Veterans General Hospital ( Site 4094)
-
Taipei, 대만, 10449
- MacKay Memorial Hospital ( Site 4092)
-
Taipei, 대만, 11217
- Taipei Veterans General Hospital ( Site 4093)
-
Taoyuan, 대만, 33305
- Linkou Chang Gung Memorial Hospital ( Site 4091)
-
-
-
-
-
Seoul, 대한민국, 03722
- Severance Hospital Yonsei University Health System ( Site 4062)
-
Seoul, 대한민국, 05505
- Asan Medical Center ( Site 4061)
-
Seoul, 대한민국, 06351
- Samsung Medical Center ( Site 4064)
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, 대한민국, 10408
- National Cancer Center ( Site 4065)
-
Seongnam-si, Kyonggi-do, 대한민국, 13620
- Seoul National University Bundang Hospital ( Site 4063)
-
-
-
-
Capital Region
-
Copehagen, Capital Region, 덴마크, 2100
- Rigshospitalet University Hospital ( Site 2515)
-
Herlev, Capital Region, 덴마크, 2730
- Herlev Hospital ( Site 2514)
-
-
North Denmark
-
Aalborg, North Denmark, 덴마크, 9100
- Aalborg Universitetshospital ( Site 2511)
-
-
Region Sjælland
-
Roskilde, Region Sjælland, 덴마크, 4000
- Roskilde Sygehus ( Site 2513)
-
-
Region Syddanmark
-
Odense, Region Syddanmark, 덴마크, 5000
- Odense Universitetshospital ( Site 2512)
-
-
-
-
Baden-Wurttemberg
-
Heilbronn, Baden-Wurttemberg, 독일, 74078
- SLK-Kliniken Heilbronn GmbH ( Site 2116)
-
Ludwigsburg, Baden-Wurttemberg, 독일, 71640
- Klinikum Ludwigsburg ( Site 2111)
-
Tübingen, Baden-Wurttemberg, 독일, 72076
- Universitaetsklinikum Tuebingen ( Site 2113)
-
-
Lower Saxony
-
Hanover, Lower Saxony, 독일, 30625
- Medizinische Hochschule Hannover-Department of Obstetrics and Gynecology ( Site 2109)
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, 독일, 53127
- Universitätsklinikum Bonn-Gynaecological oncology ( Site 2103)
-
Essen, North Rhine-Westphalia, 독일, 45136
- Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 2105)
-
-
Saxony
-
Dresden, Saxony, 독일, 01307
- Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur ( Site 2104)
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, 독일, 23538
- Universitätsklinikum Schleswig-Holstein ( Site 2101)
-
-
-
-
Arkhangelskaya oblast
-
Arkhangelsk, Arkhangelskaya oblast, 러시아 제국, 163045
- Arkhangelsk Clinical Oncological Dispensary ( Site 2637)
-
-
Baskortostan, Respublika
-
Ufa, Baskortostan, Respublika, 러시아 제국, 450054
- Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 2645)
-
-
Chelyabinsk Oblast
-
Chelyabinsk, Chelyabinsk Oblast, 러시아 제국, 454087
- Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)
-
-
Krasnoyarsk Krai
-
Krasnoyarsk, Krasnoyarsk Krai, 러시아 제국, 660133
- Krasnoyarsk Regional Clinical oncology dispensary ( Site 2643)
-
-
Mordoviya, Respublika
-
Saransk, Mordoviya, Respublika, 러시아 제국, 430032
- National Research Ogarev Mordovia State University ( Site 2648)
-
-
Moscow
-
Moscow, Moscow, 러시아 제국, 115522
- Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF Dep.of antitumor drug therapy #4 ( Site 2634)
-
Moscow, Moscow, 러시아 제국, 125284
- Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2631)
-
-
Nizhny Novgorod Oblast
-
Nizhny Novgorod, Nizhny Novgorod Oblast, 러시아 제국, 603126
- Scientific Research Institute of Clinical Oncology "Nizhegorodsky Regional Oncology Dospensary" ( Site 2639)
-
-
Samara Oblast
-
Samara, Samara Oblast, 러시아 제국, 443031
- Samara Regional Clinical Oncology Center-Chemotherapy Dapartment ( Site 2649)
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, 러시아 제국, 197758
- Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2636)
-
-
Tatarstan, Respublika
-
Kazan', Tatarstan, Respublika, 러시아 제국, 420029
- Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2646)
-
-
Tomsk Oblast
-
Tomsk, Tomsk Oblast, 러시아 제국, 634028
- Tomsk Scientific Research Institute of Oncology-Chemotherapy ( Site 2638)
-
-
Yaroslavl Oblast
-
Yaroslavl, Yaroslavl Oblast, 러시아 제국, 150054
- Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2641)
-
-
-
-
-
Mexico City, 멕시코, 06700
- Hospital Angeles Roma ( Site 1123)
-
-
Baja California Sur
-
La Paz, Baja California Sur, 멕시코, 23040
- Investigacion Onco Farmaceutica S de RL de CV ( Site 1127)
-
-
Chiapas
-
Tuxtla Gutiérrez, Chiapas, 멕시코, 29090
- Hospital San Lucas Cardiologica del Sureste ( Site 1122)
-
-
Mexico City
-
Mexico City, Mexico City, 멕시코, 04700
- Centro Oncologico Internacional. SEDNA ( Site 1121)
-
Mexico City, Mexico City, 멕시코, 14080
- Instituto Nacional de Cancerologia ( Site 1124)
-
-
Nuevo León
-
Monterrey, Nuevo León, 멕시코, 64460
- Filios Alta Medicina ( Site 1125)
-
Monterrey, Nuevo León, 멕시코, 64710
- I Can Oncology Center SA de CV ( Site 1126)
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35249
- University of Alabama - Birmingham ( Site 3061)
-
Mobile, Alabama, 미국, 36604
- University of South Alabama, Mitchell Cancer Institute ( Site 3058)
-
-
Arizona
-
Phoenix, Arizona, 미국, 85016
- HonorHealth Research Institute - Biltmore ( Site 3043)
-
Tucson, Arizona, 미국, 85711
- Arizona Oncology Associates PC- HOPE ( Site 3049)
-
-
California
-
La Jolla, California, 미국, 92093-0698
- UCSD Moores Cancer Center ( Site 3053)
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University Of Colorado ( Site 3051)
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06511
- Smilow Cancer Hospital at Yale New Haven ( Site 3070)
-
-
Florida
-
Miami Beach, Florida, 미국, 33140
- Mount Sinai Cancer Center ( Site 3081)
-
-
Georgia
-
Atlanta, Georgia, 미국, 30342
- Northside Hospital ( Site 3036)
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern Memorial Hospital ( Site 3044)
-
-
Indiana
-
Fort Wayne, Indiana, 미국, 46845
- Parkview Cancer Institute ( Site 3067)
-
Indianapolis, Indiana, 미국, 46202
- Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- University of Iowa Hospital and Clinics ( Site 3046)
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40207
- Norton Cancer Institute - St. Matthews ( Site 3056)
-
-
Louisiana
-
Shreveport, Louisiana, 미국, 71103
- WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)
-
-
Massachusetts
-
Worcester, Massachusetts, 미국, 01605
- University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 3037)
-
-
New York
-
Mineola, New York, 미국, 11501
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)
-
New York, New York, 미국, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)
-
The Bronx, New York, 미국, 10461
- Montefiore Medical Center ( Site 3065)
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Duke Cancer Center ( Site 3072)
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58102
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3066)
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Legacy Good Samaritan Medical Center ( Site 3033)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- Sidney Kimmel Cancer Center - Jefferson Health ( Site 3078)
-
Pittsburgh, Pennsylvania, 미국, 15224
- AHN West Penn Hospital ( Site 3060)
-
Willow Grove, Pennsylvania, 미국, 19090
- Abington Hospital - Asplundh Cancer Center ( Site 3073)
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57104
- Sanford Gynecology Oncology ( Site 3045)
-
-
Texas
-
Dallas, Texas, 미국, 75390
- UT Southwestern Medical Center ( Site 3063)
-
-
Virginia
-
Richmond, Virginia, 미국, 23298
- VCU Massey Cancer Center ( Site 3068)
-
-
-
-
-
Liège, 벨기에, 4000
- CHC - Groupe Sante ( Site 2041)
-
Liège, 벨기에, 4000
- CHU Liege Sart-Tilman ( Site 2044)
-
-
Bruxelles-Capitale, Region de
-
Brussels, Bruxelles-Capitale, Region de, 벨기에, 1200
- Saint-Luc UCL ( Site 2042)
-
-
Hainaut
-
Mons, Hainaut, 벨기에, 7000
- C.I.U. Hopital Ambroise Pare ( Site 2039)
-
-
Liege
-
Verviers, Liege, 벨기에, 4800
- CHR Verviers ( Site 2035)
-
-
Oost-Vlaanderen
-
Aalst, Oost-Vlaanderen, 벨기에, 9300
- AZORG Campus Aalst-Moorselbaan ( Site 2038)
-
Ghent, Oost-Vlaanderen, 벨기에, 9000
- AZ Maria Middelares Gent ( Site 2032)
-
Ghent, Oost-Vlaanderen, 벨기에, 9000
- Universitair Ziekenhuis Gent ( Site 2037)
-
Sint-Niklaas, Oost-Vlaanderen, 벨기에, 9100
- AZ Nikolaas ( Site 2031)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, 벨기에, 3000
- UZ Leuven ( Site 2040)
-
-
West-Vlaanderen
-
Kortrijk, West-Vlaanderen, 벨기에, 8500
- AZ Groeninge ( Site 2036)
-
-
-
-
Stockholm County
-
Solna, Stockholm County, 스웨덴, 171 76
- Karolinska Universitetssjukhuset Solna ( Site 2220)
-
-
Uppsala County
-
Uppsala, Uppsala County, 스웨덴, 751 85
- Blod-och Tumorsjukdomar ( Site 2221)
-
-
Östergötland County
-
Linköping, Östergötland County, 스웨덴, 581 85
- Universitetssjukhuset i Linkoping. ( Site 2222)
-
-
-
-
-
Barcelona, 스페인, 08035
- Hospital Vall D Hebron ( Site 2182)
-
Barcelona, 스페인, 08036
- Hospital Clinic i Provincial ( Site 2185)
-
Córdoba, 스페인, 14004
- Hospital Universitario Reina Sofia ( Site 2183)
-
Madrid, 스페인, 28040
- Hospital Clinico San Carlos ( Site 2187)
-
Madrid, 스페인, 28046
- Hospital Universitario La Paz ( Site 2186)
-
-
Gerona
-
Girona, Gerona, 스페인, 17007
- Institut Català d'Oncologia (ICO) - Girona ( Site 2184)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, 스페인, 28027
- Clinica Universitaria de Navarra ( Site 2181)
-
-
-
-
-
Buenos Aires, 아르헨티나, C1012AAR
- IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 1010)
-
Buenos Aires, 아르헨티나, C1118AAT
- Hospital Aleman ( Site 1001)
-
La Rioja, 아르헨티나, F5300COE
- Centro Oncologico Riojano Integral ( Site 1007)
-
-
Buenos Aires
-
Berazategui, Buenos Aires, 아르헨티나, B1884BBF
- Centro de Oncología e Investigación de Buenos Aires ( Site 1005)
-
CABA, Buenos Aires, 아르헨티나, C1012AAR
- IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)
-
CABA, Buenos Aires, 아르헨티나, C1431FWO
- CEMIC ( Site 1009)
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, 아르헨티나, C1280AEB
- Hospital Britanico de Buenos Aires ( Site 1002)
-
Mar del Plata, Buenos Aires, 아르헨티나, B7600FZO
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, 아르헨티나, S2000KZE
- Instituto de Oncologia de Rosario ( Site 1004)
-
-
-
-
-
Leicester, 영국, LE1 5WW
- Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 2249)
-
Manchester, 영국, M20 4BX
- The Christie Hospital NHS Foundation Trust ( Site 2243)
-
-
Bristol, City of
-
Bristol, Bristol, City of, 영국, BS2 8ED
- Bristol Haematology and Oncology Centre ( Site 2244)
-
-
East Riding Of Yorkshire
-
Cottingham, East Riding Of Yorkshire, 영국, HU165JQ
- Castle Hill Hospital-Academic Oncology ( Site 2252)
-
-
Glasgow City
-
Glasgow, Glasgow City, 영국, G12 0YN
- Beatson West of Scotland Cancer Centre ( Site 2247)
-
-
London, City of
-
London, London, City of, 영국, NW1 2PG
- UCLH NHS Foundation Trust ( Site 2242)
-
London, London, City of, 영국, SW3 6JJ
- Royal Marsden NHS Foundation Trust ( Site 2248)
-
Sutton, London, City of, 영국, SM2 5PT
- Royal Marsden Hospital Sutton-Surrey ( Site 2241)
-
-
-
-
Styria
-
Graz, Styria, 오스트리아, 8036
- Medizinische Universitat Graz ( Site 2004)
-
-
Tyrol
-
Innsbruck, Tyrol, 오스트리아, 6020
- Medizinische Universitaet Innsbruck ( Site 2001)
-
-
-
-
Chernihiv Oblast
-
Chernihiv, Chernihiv Oblast, 우크라이나, 14029
- Chernihiv Medical Center of Modern Oncology ( Site 2368)
-
-
Chernivetska Oblast
-
Chernivtsi, Chernivetska Oblast, 우크라이나, 58013
- Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 2366)
-
-
Kharkiv Oblast
-
Kharkiv, Kharkiv Oblast, 우크라이나, 61024
- SO Grigoriev Institute for Medical Radiology and Oncology of NAMS of Ukraine ( Site 2363)
-
-
Khmelnytskyi Oblast
-
Khmelnitskyi, Khmelnytskyi Oblast, 우크라이나, 29009
- MNE "Khmelnytskyi regional antitumor center" ( Site 2365)
-
-
Kyivska Oblast
-
Kiev, Kyivska Oblast, 우크라이나, 08720
- LISOD - Israeli Oncological Hospital MedX-ray International Group LLC ( Site 2364)
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, 우크라이나, 79031
- Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2361)
-
-
Volyn Oblast
-
Lutsk, Volyn Oblast, 우크라이나, 43018
- Volyn Regional Clinical Hospital Regional Medical Oncology Centre ( Site 2362)
-
-
-
-
-
Haifa, 이스라엘, 3525408
- Rambam Medical Center ( Site 2307)
-
Holon, 이스라엘, 5810001
- Edith Wolfson Medical Center ( Site 2306)
-
Jerusalem, 이스라엘, 9112001
- Hadassah Medical Center. Ein Kerem ( Site 2303)
-
Petah Tikva, 이스라엘, 4941492
- Rabin Medical Center ( Site 2305)
-
Ramat Gan, 이스라엘, 5265601
- Chaim Sheba Medical Center ( Site 2301)
-
-
-
-
-
Brescia, 이탈리아, 25123
- Azienda Ospedaliera Spedali Civili di Brescia ( Site 2135)
-
Milan, 이탈리아, 20132
- IRCCS Ospedale San Raffaele ( Site 2130)
-
Milan, 이탈리아, 20141
- Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 2132)
-
Naples, 이탈리아, 80131
- Azienda Ospedaliera Universitaria Federico II ( Site 2123)
-
Naples, 이탈리아, 80131
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2127)
-
Padova, 이탈리아, 35128
- Istituto Oncologico Veneto IRCCS-Oncologia 2 ( Site 2134)
-
-
Abruzzo
-
Roma, Abruzzo, 이탈리아, 00144
- Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 2121)
-
-
Lazio
-
Rome, Lazio, 이탈리아, 00168
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 2124)
-
-
Lombardy
-
Milan, Lombardy, 이탈리아, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2122)
-
-
Piedmont
-
Candiolo, Piedmont, 이탈리아, 10060
- INOC - Istituto Nazionale Oncologico Candiolo ( Site 2125)
-
-
-
-
-
Fukuoka, 일본, 811-1395
- National Hospital Organization Kyushu Cancer Center ( Site 4193)
-
Niigata, 일본, 951-8566
- Niigata Cancer Center Hospital ( Site 4185)
-
Osaka, 일본, 541-8567
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 4188)
-
Tokyo, 일본, 160-8582
- Keio University Hospital ( Site 4191)
-
Tokyo, 일본, 135-8550
- Cancer Institute Hospital of JFCR ( Site 4196)
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 464-8681
- Aichi Cancer Center ( Site 4190)
-
-
Chiba
-
Kashiwa, Chiba, 일본, 277-8577
- National Cancer Center Hospital East ( Site 4197)
-
-
Ehime
-
Matsuyama, Ehime, 일본, 791-0280
- National Hospital Organization Shikoku Cancer Center ( Site 4181)
-
Tōon, Ehime, 일본, 791-0295
- Ehime University Hospital ( Site 4187)
-
-
Fukuoka
-
Kurume, Fukuoka, 일본, 830-0011
- Kurume University Hospital ( Site 4186)
-
-
Gunma
-
Ōta, Gunma, 일본, 373-8550
- Gunma Prefectural Cancer Center ( Site 4183)
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본, 060-8648
- Hokkaido University Hospital ( Site 4194)
-
-
Hyōgo
-
Akashi, Hyōgo, 일본, 673-8558
- Hyogo Cancer Center ( Site 4195)
-
-
Iwate
-
Shiwa-gun, Iwate, 일본, 028-3695
- Iwate Medical University Hospital ( Site 4189)
-
-
Okinawa
-
Ginowan, Okinawa, 일본, 901-2725
- University of the Ryukyus Hospital ( Site 4184)
-
-
Saitama
-
Hidaka, Saitama, 일본, 350-1298
- Saitama Medical University International Medical Center ( Site 4182)
-
-
Shizuoka
-
Suntogun, Shizuoka, 일본, 411-8777
- Shizuoka Cancer Center ( Site 4192)
-
-
-
-
Anhui
-
Hefei, Anhui, 중국, 230001
- Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 4034)
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100036
- Beijing Cancer Hospital ( Site 4048)
-
Beijing, Beijing Municipality, 중국, 100730
- Peking Union Medical College Hospital ( Site 4036)
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, 중국, 400030
- Chongqing Cancer Hospital ( Site 4040)
-
-
Fujian
-
Xiamen, Fujian, 중국, 361003
- The First Affiliated Hospital of Xiamen University ( Site 4060)
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510080
- The First Affiliated Hospital ( Site 4043)
-
-
Guangxi
-
Nanning, Guangxi, 중국, 530221
- Guangxi Medical University Affiliated Tumor Hospital ( Site 4049)
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국, 150081
- Harbin Medical University Cancer Hospital ( Site 4033)
-
-
Hubei
-
Wuhan, Hubei, 중국, 430079
- Hubei Cancer Hospital ( Site 4059)
-
-
Hunan
-
Changsha, Hunan, 중국, 410006
- Hunan Cancer Hospital ( Site 4050)
-
Changsha, Hunan, 중국, 410008
- Xiangya Hospital Central South University ( Site 4035)
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210008
- Nanjing Drum Tower Hospital ( Site 4037)
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 530021
- Jiangxi Maternal and Child Health Hospital ( Site 4051)
-
-
Jilin
-
Changchun, Jilin, 중국, 130000
- The First Hospital of Jilin University ( Site 4057)
-
-
Shaanxi
-
Xi'an, Shaanxi, 중국, 710061
- The First Affiliated Hospital of Xi an Jiaotong University ( Site 4045)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200090
- Obstetrics and Gynecology Hosp. Fudan University ( Site 4041)
-
Shanghai, Shanghai Municipality, 중국, 200127
- Shanghai Renji Hospital Affiliated to Jiao Tong University ( Site 4053)
-
Shanghai, Shanghai Municipality, 중국, 201204
- Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 4001)
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- Sichuan Cancer Hospital. ( Site 4039)
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, 중국, 300000
- Tianjin Medical University Cancer Institute & Hospital ( Site 4054)
-
-
Yunnan
-
Kunming, Yunnan, 중국, 650107
- Yunnan Province Cancer Hospital-Gynecology Department ( Site 4055)
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 310003
- The First Affiliated Hospital, Zhejiang University-Gynecology ( Site 4002)
-
Hangzhou, Zhejiang, 중국, 310006
- Women s Hospital School of Medicine Zhejiang University ( Site 4032)
-
Wenzhou, Zhejiang, 중국, 325000
- The First Affiliated Hospital of Wenzhou Medical University ( Site 4056)
-
-
-
-
-
Olomouc, 체코, 77900
- Fakultni nemocnice Olomouc ( Site 2392)
-
-
Brno-mesto
-
Brno, Brno-mesto, 체코, 62500
- Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 2394)
-
-
Praha 10
-
Prague, Praha 10, 체코, 100 34
- Fakultni nemocnice Kralovske Vinohrady ( Site 2393)
-
-
Praha 2
-
Prague, Praha 2, 체코, 128 08
- Vseobecna fakultni nemocnice v Praze ( Site 2391)
-
-
-
-
Araucania
-
Temuco, Araucania, 칠레, 4800827
- Centro Investigación del Cáncer James Lind ( Site 1061)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, 칠레, 7500921
- Fundacion Arturo Lopez Perez FALP ( Site 1062)
-
Santiago, Region M. de Santiago, 칠레, 8330032
- Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063)
-
Santiago, Region M. de Santiago, 칠레, 8420383
- Bradfordhill-Clinical Area ( Site 1070)
-
-
Valparaiso
-
Viña del Mar, Valparaiso, 칠레, 2520598
- Oncocentro ( Site 1065)
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 3007)
-
-
Ontario
-
Kingston, Ontario, 캐나다, K7L 2V7
- Kingston Health Sciences Centre ( Site 3003)
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2X 0C1
- Centre Hospitalier de l Universite de Montreal - CHUM ( Site 3006)
-
Montreal, Quebec, 캐나다, H4A 3J1
- McGill University Health Centre ( Site 3005)
-
Québec, Quebec, 캐나다, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 3002)
-
-
-
-
Antioquia
-
Medellín, Antioquia, 콜롬비아, 050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 1096)
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., 콜롬비아, 111511
- Instituto Nacional de Cancerología E.S.E ( Site 1094)
-
-
Departamento de Nariño
-
Pasto, Departamento de Nariño, 콜롬비아, 520002
- Instituto Cancerologico de Nariño S.A.S. ( Site 1092)
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, 콜롬비아, 760032
- Fundación Valle del Lili ( Site 1093)
-
-
-
-
-
Adana, 터키 (Türkiye), 01250
- Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2355)
-
Adana, 터키 (Türkiye), 01330
- Cukurova Uni. Tip Fakultesi ( Site 2353)
-
Ankara, 터키 (Türkiye), 06490
- Baskent Universitesi Ankara Hastanesi ( Site 2354)
-
Ankara, 터키 (Türkiye), 06590
- Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 2350)
-
Istanbul, 터키 (Türkiye), 34214
- Medipol Universite Hastanesi ( Site 2352)
-
Izmir, 터키 (Türkiye), 35100
- Ege University Medical Faculty ( Site 2351)
-
Izmir, 터키 (Türkiye), 35575
- I.E.U. Medical Point Hastanesi ( Site 2356)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, 폴란드, 61-866
- Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 2484)
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, 폴란드, 08-110
- Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2487)
-
Warsaw, Masovian Voivodeship, 폴란드, 00-315
- Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 2481)
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, 폴란드, 15-027
- Bialostockie Centrum Onkologii ( Site 2483)
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, 폴란드, 44-102
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2482)
-
-
Warmian-Masurian Voivodeship
-
Olsztyn, Warmian-Masurian Voivodeship, 폴란드, 10-228
- Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2486)
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, 폴란드, 25-734
- Swietokrzyskie Centrum Onkologii. ( Site 2485)
-
-
-
-
Ain
-
Vandœuvre-lès-Nancy, Ain, 프랑스, 54519
- Institut De Cancerologie De Lorraine ( Site 2072)
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, 프랑스, 06189
- Centre Antoine Lacassagne ( Site 2073)
-
-
Calvados
-
Caen, Calvados, 프랑스, 14076
- Centre Francois Baclesse ( Site 2062)
-
-
Cotes-d Armor
-
Plérin, Cotes-d Armor, 프랑스, 22190
- Hôpital Privé Des Côtes d'Armor ( Site 2063)
-
-
Doubs
-
Besançon, Doubs, 프랑스, 25000
- CHU Besancon - Hopital Jean Minjoz ( Site 2068)
-
-
Gironde
-
Bordeaux, Gironde, 프랑스, 33076
- Institut Bergonie ( Site 2067)
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, 프랑스, 31059
- Institut Universitaire du Cancer Toulouse - Oncopole ( Site 2065)
-
-
Herault
-
Montpellier, Herault, 프랑스, 34298
- Institut Regional du Cancer de Montpellier - ICM ( Site 2069)
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, 프랑스, 44277
- Hopital prive du Confluent ( Site 2061)
-
-
Rhone
-
Pierre-Bénite, Rhone, 프랑스, 69310
- Centre Hospitalier Lyon Sud ( Site 2064)
-
-
Île-de-France Region
-
Paris, Île-de-France Region, 프랑스, 75014
- Hopital Cochin ( Site 2070)
-
Villejuif, Île-de-France Region, 프랑스, 94805
- Gustave Roussy ( Site 2071)
-
-
-
-
Northern Savonia
-
Kuopio, Northern Savonia, 핀란드, 70210
- Kuopio University Hospital ( Site 2543)
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, 핀란드, 33520
- Tampere University Hospital ( Site 2541)
-
-
Southwest Finland
-
Turku, Southwest Finland, 핀란드, 20520
- Turku University Hospital ( Site 2542)
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Has a histologically confirmed new diagnosis of Endometrial Carcinoma or Carcinosarcoma (Mixed Mullerian Tumor) and:
- Has undergone curative intent surgery that included hysterectomy and bilateral salpingo-oophorectomy; and
- Is at high risk for recurrence following treatment with curative intent surgery, ie: Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2009 surgical stage I/II with myometrial invasion of non-endometrioid histology; FIGO 2009 surgical stage I/II with myometrial invasion of any histology with known aberrant p53 expression or p53 mutation; or FIGO (2009) surgical stage III or IVA of any histology.
-
Is disease-free with no evidence of loco-regional disease or distant metastasis post operatively and on imaging.
-
Has not received any radiation or systemic therapy, including immunotherapy, hormonal therapy, or hyperthermic intraperitoneal chemotherapy (HIPEC), in any setting including the neoadjuvant setting for endometrial cancer (EC).
-
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
-
Submission of a tumor tissue sample from current diagnosis of Endometrial Carcinoma or Carcinosarcoma for prospective determination of histology and mismatch repair (MMR) status by central vendor is required for all participants.
-
Has adequate organ function within 7 days of randomization.
Exclusion Criteria:
-
Has recurrent endometrial carcinoma or carcinosarcoma.
-
Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas are also not allowed.
-
Has FIGO (2009) Surgical Stage I/II EC of endometrioid histology without a known aberrant p53 expression or p53 mutation.
-
Is known to have a deoxyribonucleic acid (DNA) polymerase epsilon catalytic subunit A (POLE) mutation.
-
Has FIGO Stage IVB disease of any histology even if there is no evidence of disease after surgery.
-
Has residual tumor whether measurable or non-measurable after surgery.
-
Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
- Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers.
-
Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
-
Has received a live vaccine within 30 days before the first dose of study intervention.
- Note: killed vaccines are allowed.
-
Has a known intolerance to study intervention (or any of the excipients).
-
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
- Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
-
Has any contraindication to the use of carboplatin or paclitaxel.
-
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
-
Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
-
Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
-
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
-
Has an active infection requiring systemic therapy.
-
Has a known history of HIV infection.
-
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
-
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
-
Has had an allogenic tissue/solid organ transplant.
-
Has not recovered adequately from surgery and/or any complications from the surgery.
-
Is breastfeeding.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Pembrolizumab + Chemotherapy
Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation. |
IV infusion
다른 이름들:
IV infusion IV infusion IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel. Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
다른 이름들:
≥4500 cGY given according to local practice, at the discretion of the investigator If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
다른 이름들:
Given according to local practice, at the discretion of the investigator
다른 이름들:
|
|
위약 비교기: Placebo + Chemotherapy
Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation. |
IV infusion IV infusion IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel. Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
다른 이름들:
≥4500 cGY given according to local practice, at the discretion of the investigator If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
다른 이름들:
Given according to local practice, at the discretion of the investigator
다른 이름들:
IV infusion |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence
기간: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence, will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS)
기간: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 54 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Blinded Independent Central Review (BICR) or by Histopathologic Confirmation of Suspected Disease Recurrence
기간: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by BICR or by histopathologic confirmation of suspected disease recurrence, will be presented. |
Up to approximately 42 months
|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
기간: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
기간: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented. |
Up to approximately 54 months
|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
기간: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status, will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
기간: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status will be presented. |
Up to approximately 54 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
기간: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 54 months
|
|
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
기간: Up to approximately 52 weeks
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 52 weeks
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (QoL) Score
기간: Baseline and up to approximately 54 months
|
The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. Participant responses to questions 29 ("How would you rate your overall health during the past week?") and 30 ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented. |
Baseline and up to approximately 54 months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Function Score
기간: Baseline and up to approximately 54 months
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented. |
Baseline and up to approximately 54 months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Endometrial Cancer (EORTC QLQ-EN24) Score
기간: Baseline and up to approximately 54 months
|
The EORTC-QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in EORTC QLQ-E24 score will be presented. |
Baseline and up to approximately 54 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Medical Director, Merck Sharp & Dohme LLC
간행물 및 유용한 링크
일반 간행물
- Van Gorp T, Cibula D, Lv W, Backes F, Ortac F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B; ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024 Nov;35(11):968-980. doi: 10.1016/j.annonc.2024.08.2242. Epub 2024 Sep 14.
- Slomovitz BM, Cibula D, Lv W, Ortac F, Hietanen S, Backes F, Kikuchi A, Lorusso D, Danska-Bidzinska A, Samouelian V, Barretina-Ginesta MP, Vulsteke C, Lai CH, Pothuri B, Zhang Y, Magallanes-Maciel M, Amit A, Guarneri V, Zagouri F, Bell M, Welz J, Eminowicz G, Hruda M, Willmott LJ, Lichfield J, Wang W, Orlowski R, Aktan G, Gladieff L, Van Gorp T. Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. J Clin Oncol. 2025 Jan 20;43(3):251-259. doi: 10.1200/JCO-24-01887. Epub 2024 Oct 16.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 생식기 질환
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 자궁 질환
- 생식기 질환, 여성
- 생식기 신생물, 여성
- 자궁 신생물
- 자궁내막 신생물
- 파킨슨 병 4, 상 염색체 우성 루이 바디
- 유기 화학 물질
- 치료학
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 조정 복합체
- 박습니다
- 사이클로 데카네
- Diterpenes
- 백금 화합물
- 방사선 요법
- 도세탁셀
- 카르보플라틴
- 파클리탁셀
- 시스플라틴
- 펨브 롤리 주맙
- 상완골
기타 연구 ID 번호
- 3475-B21
- KEYNOTE-B21 (기타 식별자: MSD)
- ENGOT-en11 (기타 식별자: European Network for Gynaecological Oncological Trial groups)
- GOG-3053 (기타 식별자: Gynecologic Oncology Group)
- jRCT2031200399 (레지스트리 식별자: jRCT)
- 2020-003424-17 (EudraCT 번호)
- 2022-501973-37-00 (레지스트리 식별자: EU CT)
- U1111-1282-6430 (레지스트리 식별자: UTN)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .